Streetbeat News

Stock Prices

AG

CDE

FSM

PAAS

Shares of precious metals companies are trading higher due to recent increases in gold and silver prices.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 5:03 pm

NVRO

Analyst ratings for Nevro (NYSE:NVRO) have remained neutral over the last quarter, with all four analysts giving indifferent ratings. The 12-month price targets have been adjusted downwards, with an average target now at $18.00, down from a previous average of $21.00. Analysts from Citigroup, Wells Fargo, Baird, and RBC Capital have all lowered their price targets for NVRO, reflecting changing market dynamics and company performance. Nevro, a medical device company specializing in the HFX spinal cord stimulation platform, has shown a positive revenue trend with a growth rate of 2.05% as of December 31, 2023, but lags behind industry peers. The company's financial performance is strong, with exceptional net margin and ROE exceeding industry averages, and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:01 pm

KVUE

Analysts have recently provided mixed reviews on Kenvue (NYSE:KVUE), with sentiments ranging from bullish to bearish over the past three months. The average 12-month price target for KVUE is now $22.4, a decrease from the previous $24.00. Kenvue, a spin-off from Johnson & Johnson and the world's largest pure-play consumer health company, has seen a revenue decline of -2.68% as of December 31, 2023, but maintains strong financial health indicators such as net margin and ROE.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm

SYK

Nine financial analysts have recently provided ratings on Stryker (NYSE:SYK), with a mix of bullish and somewhat bullish perspectives dominating. The average 12-month price target for SYK has been raised to $361.11, indicating a 6.52% increase from the previous target of $339.00. Analysts from firms including Citigroup, RBC Capital, Truist Securities, Roth MKM, Canaccord Genuity, and Wells Fargo have adjusted their ratings and price targets, reflecting a positive outlook on Stryker's performance. Stryker's financial indicators such as market capitalization, revenue growth, net margin, ROE, and ROA are strong, although its debt-to-equity ratio suggests potential financial challenges.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm

GXO

NDAQ

TMO

On CNBC's Halftime Report, analysts shared their final trades, highlighting GXO Logistics, Nasdaq, and Thermo Fisher Scientific as their top picks. These companies were recommended based on their current market performance and potential for future growth.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 5:00 pm

ASND

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market over the past decade, with an annualized return of 55.34%, turning a $100 investment into $8,187.29 today. The company's market capitalization stands at $8.28 billion.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm

MCK

Over the past 10 years, McKesson (NYSE:MCK) has delivered an average annual return of 12.31%, turning a $1000 investment into $3,213.89. With a current market cap of $70.78 billion, MCK has outperformed the market by 1.42% on an annualized basis.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm

ZBH

Zimmer Biomet Holdings (NYSE:ZBH) has received mixed analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for ZBH has increased by 5.57% to $134.29. Analyst actions include rating adjustments and price target changes, reflecting dynamic market conditions and company performance. Zimmer Biomet, a leader in orthopedic reconstructive implants, has shown a revenue growth of 6.3% but lags behind industry peers. Its net margin outperforms industry averages, yet its ROE is below benchmarks.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm

COTY

Coty's stock price declined following Ulta Beauty's report of weak guidance during a conference, indicating potential concerns in the beauty sector.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 4:59 pm

ABUS

MRNA

Arbutus Biopharma's stock is trading higher due to the circulation of documents related to a patent infringement lawsuit between Arbutus/Genevant and Moderna.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 4:57 pm